- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.05. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Lyell Immunopharma reports Q1 results | 2 | Seeking Alpha | ||
| 13.05. | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 | 186 | GlobeNewswire (Europe) | Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory... ► Artikel lesen | |
| 15.04. | Lyell Immunopharma gets FDA RMAT status for lymphoma treatment | 1 | Seeking Alpha | ||
| 15.04. | Lyell Immunopharma, Inc: Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma | 119 | GlobeNewswire (Europe) | RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes... ► Artikel lesen | |
| 01.04. | Lyell Immunopharma, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 11.03. | Lyell Immunopharma reports Q4 results | 2 | Seeking Alpha | ||
| 11.03. | Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Lyell Immunopharma, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 11.03. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 | 137 | GlobeNewswire (Europe) | Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large... ► Artikel lesen | |
| 11.03. | Lyell Immunopharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.01. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.12.24 | Lyell Immunopharma, Inc: Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting | 153 | GlobeNewswire (Europe) | Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior... ► Artikel lesen | |
| 10.12.24 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.10.24 | Lyell Immunopharma, Inc: Lyell Immunopharma Completes Acquisition of ImmPACT Bio | 149 | GlobeNewswire (Europe) | Acquisition strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients... ► Artikel lesen | |
| 07.08.24 | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 | 177 | GlobeNewswire (Europe) | Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR)... ► Artikel lesen | |
| 26.06.24 | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology | 213 | GlobeNewswire (Europe) | Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,133 | -4,68 % | Medigene AG: Widerruf der Zulassung (Prime Standard) | Beschluss
Medigene AG, Planegg/Martinsried
Widerruf der Zulassung zum Teilbereich des regulierten Marktes mit weiteren Zulassungsfolgepflichten (Prime Standard) von Amts wegen
Die Zulassung... ► Artikel lesen | |
| AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, INC. - 10-K, Annual Report | ||
| OCUGEN | 0,917 | -0,97 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 1,050 | 0,00 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalmaßnahme/Kapitalmaßnahme
Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
03.06.2025... ► Artikel lesen | |
| EDITAS MEDICINE | 1,681 | 0,00 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
| DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
| BURCON NUTRASCIENCE | 0,073 | +5,80 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,322 | +0,62 % | Cellectar +147%: Ich nehme die Gewinne mit! | Meine Spekulation geht auf: Cellectar Biosciences (WKN: A3DQSD) knallt heute in der Spitze um bis zu +147% durch die Decke, nachdem ich im März ein großes Comeback der Aktie in Aussicht gestellt hatte.... ► Artikel lesen | |
| GALAPAGOS NV | 24,420 | +0,25 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new... ► Artikel lesen |
LYELL IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +9,56 % bei einem Aktienkurs von 12,555 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.